Fig. 7.

STK25 loss is common in human cancers and adversely affects patient survival. a Graphical representation of human cancers with the highest frequencies of STK25 deletion. Data was accessed using the cBioPortal online program (http://www.cbioportal.org/). b Survival data of sarcoma patients from the TCGA dataset were accessed using the Xenabrowser online program (https://xenabrowser.net/) and overall survival rates and times were assessed for patients with and without deletions of STK25 (*p = 0.0172, n = 215, log-rank test). c Proposed model of STK25 in Hippo tumor suppressor signaling